Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?

Executive Summary

Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.


Related Content

Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
Esperion Says FDA Stance Means No Clear Regulatory Path For ETC-1002
Amgen's Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors
PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT
Praluent Sponsors Set Tone For PCSK9 Labeling, Post-Marketing Negotiations
PCSK9 Revised Analysis Indicates Less Price Discounting May Be Needed
Broad Enough? Sponsors Pleased With Narrower Praluent Label
Praluent Panel To Focus On Indication Breadth Absent CV Outcomes Data
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts